From GlobeNewswire: 2025-03-27 07:00:00

Plinabulin’s final Phase 3 data published in The Lancet Respiratory Medicine shows an overall survival benefit in 2L/3L NSCLC EGFR wild type vs. Docetaxel. Phase 2 data highlights potential to resensitize tumors progressed on PD-1/PD-L1 inhibitors in metastatic NSCLC. SEED Therapeutics enters a research collaboration with Eisai with potential payments of up to $1.5 billion.

SEED Therapeutics’ lead oncology asset RBM39 Degrader granted Rare Pediatric Disease and Orphan Drug Designations by FDA. BeyondSpring reports significant progress with Plinabulin, demonstrating a survival benefit in patients with NSCLC. Plinabulin shows promising efficacy in combination with PD-1 inhibitors and docetaxel in metastatic NSCLC.

Plinabulin’s Phase 3 data, now published in The Lancet Respiratory Medicine, strengthens regulatory strategy for submission to NMPA. SEED Therapeutics secures a collaboration with Eisai, potentially receiving up to $1.5 billion. Plinabulin shows potential to resensitize tumors to checkpoint inhibitors, addressing acquired resistance in cancer patients.



Read more at GlobeNewswire:: BeyondSpring Reports 2024 Year-End Financial Results and